Sutro Biopharma Valuation
| STRO Stock | USD 2.69 0.09 3.46% |
Based on Macroaxis valuation methodology, the company appears to be undervalued. Sutro Biopharma has a current Real Value of $6.22 per share. The regular price of the company is $2.69. Our model measures the value of Sutro Biopharma from inspecting the company fundamentals such as Shares Outstanding of 82.46 M, return on equity of -1.11, and Operating Margin of (7.97) % as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Sutro Biopharma's valuation include:
Price Book 1.9944 | Enterprise Value -141.6 M | Enterprise Value Ebitda 0.4055 | Price Sales 1.3781 | Enterprise Value Revenue 0.3577 |
Undervalued
Today
Please note that Sutro Biopharma's price fluctuation is relatively risky at this time. Calculation of the real value of Sutro Biopharma is based on 3 months time horizon. Increasing Sutro Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Sutro Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Sutro Stock. However, Sutro Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.69 | Real 6.22 | Target 16.89 | Hype 2.68 | Naive 2.35 |
The intrinsic value of Sutro Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Sutro Biopharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Sutro Biopharma helps investors to forecast how Sutro stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sutro Biopharma more accurately as focusing exclusively on Sutro Biopharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Sutro Biopharma's intrinsic value based on its ongoing forecasts of Sutro Biopharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Sutro Biopharma's closest peers.
Sutro Biopharma Cash |
|
Sutro Valuation Trend
Knowing Sutro Biopharma's actual value is paramount for traders when making sound investment determinations. Using both Sutro Biopharma's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Sutro Revenue by Product
Sutro Biopharma Total Value Analysis
Sutro Biopharma is at this time projected to have valuation of (141.58 M) with market capitalization of 221.81 M, debt of 33.63 M, and cash on hands of 225.64 M. The negative valuation of Sutro Biopharma may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Sutro Biopharma fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(141.58 M) | 221.81 M | 33.63 M | 225.64 M |
Sutro Biopharma Investor Information
About 77.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.99. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sutro Biopharma has Price/Earnings To Growth (PEG) ratio of 0.12. The entity recorded a loss per share of 1.55. The firm had not issued any dividends in recent years. Based on the key measurements obtained from Sutro Biopharma's financial statements, Sutro Biopharma is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Sutro Biopharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Sutro Biopharma has an asset utilization ratio of 32.66 percent. This suggests that the Company is making $0.33 for each dollar of assets. An increasing asset utilization means that Sutro Biopharma is more efficient with each dollar of assets it utilizes for everyday operations.Sutro Biopharma Ownership Allocation
Sutro Biopharma shows a total of 82.46 Million outstanding shares. The majority of Sutro Biopharma outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Sutro Biopharma to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Sutro Biopharma. Please pay attention to any change in the institutional holdings of Sutro Biopharma as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Sutro Biopharma Profitability Analysis
The company reported the previous year's revenue of 153.73 M. Net Loss for the year was (106.79 M) with loss before overhead, payroll, taxes, and interest of (42.52 M).About Sutro Biopharma Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Sutro Biopharma. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Sutro Biopharma based exclusively on its fundamental and basic technical indicators. By analyzing Sutro Biopharma's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Sutro Biopharma's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Sutro Biopharma. We calculate exposure to Sutro Biopharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Sutro Biopharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 146.9 M | 154.3 M | |
| Pretax Profit Margin | (0.58) | (0.61) | |
| Operating Profit Margin | (0.58) | (0.61) | |
| Net Loss | (0.69) | (0.73) | |
| Gross Profit Margin | 0.96 | 1.00 |
Sutro Biopharma Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 60.2 M |
Sutro Biopharma Current Valuation Indicators
Sutro Biopharma's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Sutro Biopharma's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Sutro Biopharma, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Sutro Biopharma's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Sutro Biopharma's worth.When determining whether Sutro Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sutro Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sutro Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sutro Biopharma Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sutro Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sutro Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.55) | Revenue Per Share 2.253 | Quarterly Revenue Growth (0.50) | Return On Assets (0.18) | Return On Equity (1.11) |
The market value of Sutro Biopharma is measured differently than its book value, which is the value of Sutro that is recorded on the company's balance sheet. Investors also form their own opinion of Sutro Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sutro Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sutro Biopharma's market value can be influenced by many factors that don't directly affect Sutro Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sutro Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.